An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors. Cheng C, Zhao Y, Schaafsma E, Weng YL, et al. Int J Cancer 2020;147:2621-2633.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Cheng C, Zhao Y, Schaafsma E, Weng YL, et al. An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors. Int J Cancer 2020;147:2621-2633.
PMID: 32406930